Andrea Lisco1, Chun-Shu Wong1, Silvia Lucena Lage1, Itzchak Levy2, Jason Brophy3, Jeffrey Lennox4, Maura Manion1, Megan V Anderson1, Yolanda Mejia1, Christopher Grivas1, Harry Mystakelis1, Peter D Burbelo5, Ainhoa Perez-Diez1, Adam Rupert6, Craig A Martens7, Sarah L Anzick7, Caryn Morse1, Shanna Chan8, Claire Deleage9, Irini Sereti1. 1. Laboratory of Immunoregulation, HIV Pathogenesis Section, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA. 2. Sheba Medical Center, Tel Hashomer and the Sackler Medical School, Tel Aviv, Israel. 3. Children's Hospital of Eastern Ontario, Ottawa, Canada. 4. Grady Memorial Hospital, Emory University, Atlanta, Georgia, USA. 5. Dental Clinical Research Core, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland, USA. 6. AIDS Monitoring Laboratory, Leidos Biomedical Research, Frederick, Maryland, USA. 7. Rocky Mountain Laboratory, Genomics Unit, NIAID, NIH, Hamilton, Montana, USA. 8. Winnipeg Regional Health Authority, Manitoba, Canada. 9. Tissue Analysis Core, AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Abstract
BACKGROUND: The goal of antiretroviral therapy (ART) is to suppress HIV-1 replication and reconstitute CD4+ T cells. Here, we report on HIV-infected individuals who had a paradoxical decline in CD4+ T cells despite ART-mediated suppression of plasma HIV-1 load (pVL). We defined such an immunological outcome as extreme immune decline (EXID). METHODS: EXID's clinical and immunological characteristics were compared to immunological responders (IRs), immunological nonresponders (INRs), healthy controls (HCs), and idiopathic CD4+ lymphopenia (ICL) patients. T cell immunophenotyping and assembly/activation of inflammasomes were evaluated by flow cytometry. PBMC transcriptome analysis and genetic screening for pathogenic variants were performed. Levels of cytokines/chemokines were measured by electrochemiluminescence. Luciferase immunoprecipitation system and NK-mediated antibody-dependent cellular cytotoxicity (ADCC) assays were used to identify anti-lymphocyte autoantibodies. RESULTS: EXIDs were infected with non-B HIV-1 subtypes and after 192 weeks of consistent ART-mediated pVL suppression had a median CD4+ decrease of 157 cells/μl, compared with CD4+ increases of 193 cells/μl and 427 cells/μl in INR and IR, respectively. EXID had reduced naive CD4+ T cells, but similar proportions of cycling CD4+ T cells and HLA-DR+CD38+CD8+ T cells compared with IR and INR. Levels of inflammatory cytokines were also similar in EXID and INR, but the IL-7 axis was profoundly perturbed compared with HC, IR, INR, and ICL. Genes involved in T cell and monocyte/macrophage function, autophagy, and cell migration were differentially expressed in EXID. Two of the 5 EXIDs had autoantibodies causing ADCC, while 2 different EXIDs had an increased inflammasome/caspase-1 activation despite consistently ART-suppressed pVL. CONCLUSIONS: EXID is a distinct immunological outcome compared with previously described INR. Anti-CD4+ T cell autoantibodies and aberrant inflammasome/caspase-1 activation despite suppressed HIV-1 viremia are among the mechanisms responsible for EXID.
BACKGROUND: The goal of antiretroviral therapy (ART) is to suppress HIV-1 replication and reconstitute CD4+ T cells. Here, we report on HIV-infected individuals who had a paradoxical decline in CD4+ T cells despite ART-mediated suppression of plasma HIV-1 load (pVL). We defined such an immunological outcome as extreme immune decline (EXID). METHODS: EXID's clinical and immunological characteristics were compared to immunological responders (IRs), immunological nonresponders (INRs), healthy controls (HCs), and idiopathic CD4+ lymphopenia (ICL) patients. T cell immunophenotyping and assembly/activation of inflammasomes were evaluated by flow cytometry. PBMC transcriptome analysis and genetic screening for pathogenic variants were performed. Levels of cytokines/chemokines were measured by electrochemiluminescence. Luciferase immunoprecipitation system and NK-mediated antibody-dependent cellular cytotoxicity (ADCC) assays were used to identify anti-lymphocyte autoantibodies. RESULTS: EXIDs were infected with non-B HIV-1 subtypes and after 192 weeks of consistent ART-mediated pVL suppression had a median CD4+ decrease of 157 cells/μl, compared with CD4+ increases of 193 cells/μl and 427 cells/μl in INR and IR, respectively. EXID had reduced naive CD4+ T cells, but similar proportions of cycling CD4+ T cells and HLA-DR+CD38+CD8+ T cells compared with IR and INR. Levels of inflammatory cytokines were also similar in EXID and INR, but the IL-7 axis was profoundly perturbed compared with HC, IR, INR, and ICL. Genes involved in T cell and monocyte/macrophage function, autophagy, and cell migration were differentially expressed in EXID. Two of the 5 EXIDs had autoantibodies causing ADCC, while 2 different EXIDs had an increased inflammasome/caspase-1 activation despite consistently ART-suppressed pVL. CONCLUSIONS: EXID is a distinct immunological outcome compared with previously described INR. Anti-CD4+ T cell autoantibodies and aberrant inflammasome/caspase-1 activation despite suppressed HIV-1 viremia are among the mechanisms responsible for EXID.
Entities:
Keywords:
AIDS/HIV; Autoimmune diseases; Genetic variation; T cells
Authors: James A Garrity; Austin W Coleman; Eric L Matteson; Eric R Eggenberger; David M Waitzman Journal: Am J Ophthalmol Date: 2004-12 Impact factor: 5.258
Authors: Gregory K Robbins; John G Spritzler; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Benigno A Rodriguez; Gail Skowron; Paul R Skolnik; Robert W Shafer; Richard B Pollard Journal: Clin Infect Dis Date: 2009-02-01 Impact factor: 9.079
Authors: Ainhoa Perez-Diez; Chun-Shu Wong; Xiangdong Liu; Harry Mystakelis; Jian Song; Yong Lu; Virginia Sheikh; Jeffrey S Bourgeois; Andrea Lisco; Elizabeth Laidlaw; Cornelia Cudrici; Chengsong Zhu; Quan-Zhen Li; Alexandra F Freeman; Peter R Williamson; Megan Anderson; Gregg Roby; John S Tsang; Richard Siegel; Irini Sereti Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808